You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The method may improve the performance of circulating tumor DNA-based detection assays for routine screening and cancer relapse testing.
Boston-based NanoView aims to use its ExoView platform to understand the biological role of extracellular vesicles and their use as disease biomarkers.
BTIG highlighted the firm's cancer test portfolio, as well as its growing position in the liquid biopsy and minimal residual disease testing space.
A meta-analysis showed that early circulating tumor cell dynamics were associated with overall survival using Menarini Silicon Biosystems' CellSearch assay.
The firm will scale US-based testing capacity for its LiquidHallmark liquid biopsy assay, which uses amplicon-based technology to detect cancer-related mutations.
Ceres plans to develop its Nanotrap technology to isolate undetectable levels of circulating tumor DNA in blood samples from non-small cell lung cancer patients.
The company believes its tests can already help oncologists better assess post-surgery risk, though prospective validation would be necessary for broad claims.
The company's HCCscreen assay will be used in a liver cancer screening public health initiative, generating real-world data on the test's clinical validity and impact.
The test uses a targeted methylation sequencing panel to detect more than 50 cancer types across all stages and pinpoint a cancer's tissue of origin.
The European Commission awarded a consortium of private companies and academic researchers €759,000 recently to carry out their plans.
The company presented new evidence for the sensitivity of its multi-cancer early detection test and robustness of its automated library prep system.
The firm also discussed recent studies comparing its UltraSeek lung cancer assay with more established liquid biopsy tests to detect drug-resistant mutations.
The company reported total revenues of RMB123.9 million ($18.2 million) for the quarter, driven largely by growth in its central laboratory business.
Epic will access the center's liquid biopsy samples and expand its platform to in-depth characterization of cell-free fractions and circulating tumor cells.
The company will use a portion of the proceeds to enter into capped call transactions and the remainder for various corporate activities.
The group is developing an ultrasensitive nanoparticle-enhanced plasmonic biosensor to detect RAS single nucleotide variants in plasma.
The company also announced John Leite, the former leader of clinical business development activities at Illumina, had joined the firm as chief business officer.
Novitas added multiple leukemia biomarkers to its coverage determination, as well as the ThyGeNEXT molecular panel.
The company highlighted efforts to expand the use of its tests in the analysis of cerebrospinal fluid, an area in which research collaborations have begun to yield some data.
Despite the dramatic growth in overall testing revenue, the company's core oncology testing revenue dropped significantly quarter-over-quarter.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.